Malaga Cove Capital LLC Purchases 3,576 Shares of Bruker Co. (NASDAQ:BRKR)

Malaga Cove Capital LLC lifted its position in Bruker Co. (NASDAQ:BRKR) by 42.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,911 shares of the medical research company’s stock after acquiring an additional 3,576 shares during the quarter. Malaga Cove Capital LLC’s holdings in Bruker were worth $823,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BRKR. Covestor Ltd raised its holdings in shares of Bruker by 139.1% in the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 210 shares in the last quarter. First Horizon Advisors Inc. raised its position in Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. lifted its stake in Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker in the 2nd quarter valued at $52,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Bruker by 40.7% in the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock worth $81,000 after acquiring an additional 248 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Trading Down 3.8 %

BRKR opened at $58.98 on Thursday. Bruker Co. has a 1-year low of $54.55 and a 1-year high of $94.86. The firm has a market capitalization of $8.93 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 2.32 and a beta of 1.20. The company’s 50 day simple moving average is $63.97 and its two-hundred day simple moving average is $66.51. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 24.92% and a net margin of 11.29%. The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the prior year, the business earned $0.74 EPS. The firm’s quarterly revenue was up 16.4% on a year-over-year basis. Analysts expect that Bruker Co. will post 2.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on BRKR shares. Citigroup decreased their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Wells Fargo & Company dropped their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday. Barclays reduced their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, TD Cowen dropped their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.36.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.